Journal of Infection
Volume 61, Issue 2 , Pages 114-124 , August 2010

The risk of sequelae due to pneumococcal meningitis in high-income countries: A systematic review and meta-analysis

  • Mark Jit

      Affiliations

    • Corresponding Author InformationTel.: +44 (0)20 8327 7803; fax: +44 (0)20 8327 7868.

,Accepted 21 April 2010.

References 

  1. Pneumococcal conjugate vaccine for childhood immunization–WHO position paper. Wkly Epidemiol Rec. 2007;82:93–104
  2. Baraff LJ, Lee SI, Schriger DL. Outcomes of bacterial meningitis in children: a meta-analysis. Pediatr Infect Dis J. 1993;12:389–394
  3. Bedford H, de Louvois J, Halket S, Peckham C, Hurley R, Harvey D. Meningitis in infancy in England and Wales: follow up at age 5 years. Br Med J. 2001;323:533–536
  4. Ispahani P, Slack RCB, Donald FE, Weston VC, Rutter N. Twenty year surveillance of invasive pneumococcal disease in Nottingham: serogroups responsible and implications for immunisation. Arch Dis Child. 2004;89:757–762
  5. Weightman NCS, Sajith J. Incidence and outcome of pneumococcal meningitis in northern England. Eur J Clin Microbiol Infect Dis. 2005;24:542–544
  6. Johnson AP, Potz N, Waight P, Gungabissoon U, Livermore DM, Pebody R, et al. Susceptibility of pneumococci causing meningitis in England and Wales to first-line antimicrobial agents, 2001–2004. J Antimicrob Chemother. 2005;56:1181–1182
  7. Lieu TA, Ray GT, Black SB, Butler JC, Klein JO, Breiman RF, et al. Projected cost-effectiveness of pneumococcal conjugate vaccination of healthy infants and young children. JAMA. 2000;283:1460–1468
  8. Melegaro A, Edmunds WJ. Cost-effectiveness analysis of pneumococcal conjugate vaccination in England and Wales. Vaccine. 2004;22:4203–4214
  9. Bos JM, Rumke H, Welte R, Postma MJ, Bos JM, Rumke H, et al. Epidemiologic impact and cost-effectiveness of universal infant vaccination with a 7-valent conjugated pneumococcal vaccine in the Netherlands. Clin Ther. 2003;25:2614–2630
  10. Lebel MH, Kellner JD, Ford-Jones EL, Hvidsten K, Wang EC, Ciuryla V, et al. A pharmacoeconomic evaluation of 7-valent pneumococcal conjugate vaccine in Canada. Clin Infect Dis. 2003;36:259–268
  11. Ess SMS. Cost-effectiveness of a pneumococcal conjugate immunisation program for infants in Switzerland. Vaccine. 4, 2003;21:
  12. McIntosh ED, Conway P, Willingham J, Lloyd A, McIntosh ED, Conway P, et al. The cost-burden of paediatric pneumococcal disease in the UK and the potential cost-effectiveness of prevention using 7-valent pneumococcal conjugate vaccine. Vaccine. 2003;21:2564–2572
  13. van de Beek D, de Gans J, Spanjaard L, Weisfelt M, Reitsma JB, Vermeulen M. Clinical features and prognostic factors in adults with bacterial meningitis. N Engl J Med. 2004;351:1849–1859
  14. Weisfelt M, van de Beek D, Spanjaard L, Reitsma JB, de Gans J. Clinical features, complications, and outcome in adults with pneumococcal meningitis: a prospective case series. Lancet Neurol. 2006;5:123–129
  15. De Gans J, Van d Beek D. European dexamethasone in adulthood bacterial meningitis study investigators. Dexamethasone in adults with bacterial meningitis. N Engl J Med. 2002;347:1549–1596
  16. Weisfelt M, Hoogman M, van de Beek D, de Gans J, Dreschler WA, Schmand BA. Dexamethasone and long-term outcome in adults with bacterial meningitis. Ann Neurol. 2006;60:456–468
  17. Kellner JDS, Scheifele DW, Halperin SA, Lebel MH, Moore D, Le Saux N, et al. Outcome of penicillin-nonsusceptible Streptococcus pneumoniae meningitis: a nested case-control study. Pediatr Infect Dis J. 2002;21:903–909
  18. National Committee for Clinical Laboratory Standards . Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A5 5th ed. Wayne, PA: National Committee for Clinical Laboratory Standards; 2000;
  19. Efron B, Tibshirani RJ. An introduction to the bootstrap. Baton Rouge, FL: Chapman & Hall/CRC; 1998;
  20. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–188
  21. Kutz JW, Simon LM, Chennupati SK, Giannoni CM, Manolidis S, Kutz JW, et al. Clinical predictors for hearing loss in children with bacterial meningitis. Arch Otolaryngol Head Neck Surg. 2006;132:941–945
  22. Centers for Disease Control and Prevention (CDC) . Progress in introduction of pneumococcal conjugate vaccine–worldwide, 2000–2008. MMWR Morb Mortal Wkly Rep. 2008;57:1148–1151
  23. Wasier AP, Chevret L, Essouri S, Durand P, Chevret S, Devictor D. Pneumococcal meningitis in a pediatric intensive care unit: prognostic factors in a series of 49 children. Pediatr Crit Care Med. 2005;6:568–572
  24. Pikis A, Andrianopoulos P, Kavaliotis J, Venzon D, Tsikoulas J, Manios S. Long-term sequelae of pneumococcal meningitis in children. Clin Pediatr (Phila). 1996;35:72–78
  25. Letson GWG, Gellin BG, Bulkow LR, Parks DJ, Ward JI. Severity and frequency of sequelae of bacterial meningitis in Alaska Native infants: correlation with a scoring system for severity of sequelae. Am J Dis Child. 1992;146:560–565
  26. Rasmussen N, Johnsen NJ, Bohr VA. Otologic sequelae after pneumococcal meningitis: a survey of 164 consecutive cases with a follow-up of 94 survivors. Laryngoscope. 1991;101:876–882
  27. Kilpi T, Peltola H, Jauhiainen T, Kallio MJT, The Finnish Study Group . Oral glycerol and intravenous dexamethasone in preventing neurologic and audiologic sequelae of childhood bacterial meningitis. Pediatr Infect Dis J. 1995;14:270–278
  28. Thomas DG. Outcome of paediatric bacterial meningitis 1979–1989. Med J Aust. 1992;157:519–520
  29. Auburtin M, Porcher R, Bruneel F, Scanvic A, Trouillet JL, Bedos JP, et al. Pneumococcal meningitis in the intensive care unit: prognostic factors of clinical outcome in a series of 80 cases. Am J Respir Crit Care Med. 2002;165:713–717
  30. Ishiwada N, Kurosaki T, Terashima I, Kohno Y. The incidence of pediatric invasive pneumococcal disease in Chiba prefecture, Japan (2003–2005). J Infect. 2008;57:455–458
  31. Arditi M, Mason EO, Bradley JS, Tan TQ, Barson WJ, Schutze GE, et al. Three-year multicenter surveillance of pneumococcal meningitis in children: clinical characteristics, and outcome related to penicillin susceptibility and dexamethasone use. Pediatrics. 1998;102:1087–1097
  32. Auburtin M, Wolff M, Charpentier J, Varon E, Le TY, Girault C, et al. Detrimental role of delayed antibiotic administration and penicillin-nonsusceptible strains in adult intensive care unit patients with pneumococcal meningitis: the PNEUMOREA prospective multicenter study. Crit Care Med. 2006;34:2758–2765
  33. Benca J, Lesnakova A, Holeckova K, Ondrusova A, Wiczmandyova O, Sladecko V, et al. Pneumococcal meningitis in community is frequent after craniocerebral trauma and in alcohol abusers. Neuroendocrinol Lett. 2007;28(Suppl. 3):16–17
  34. Buckingham SCM, McCullers JA, Lujan-Zilbermann J, Knapp KM, Orman KL, English BK. Early vancomycin therapy and adverse outcomes in children with pneumococcal meningitis. Pediatrics. 2006;117:1688–1694
  35. Casado-Flores J, Aristegui J, de Liria CR, Martinon JM, Fernandez C, Spanish Pneumococcal Meningitis Study Group . Clinical data and factors associated with poor outcome in pneumococcal meningitis. Eur J Pediatr. 2006;165:285–289
  36. Davis CWC, McIntyre PB. Invasive pneumococcal infection in children, 1981-92: a hospital-based study. J Paediatr Child Health. 1995;31:317–322
  37. de Lalla F, Nicolin R, Lazzarini L. Safety and efficacy of recombinant granulocyte colony-stimulating factor as an adjunctive therapy for Streptococcus pneumoniae meningitis in non-neutropenic adult patients: a pilot study. J Antimicrob Chemother. 2000;46:843–846
  38. Eriksson M, Henriques B, Ekdahl K. Epidemiology of pneumococcal infections in Swedish children. International Journal of Paediatrics Acta Paediatrica. 2000;89(Suppl 435):35–39
  39. Faella F, Pagliano P, Fusco U, Attanasio V, Conte M. Combined treatment with ceftriaxone and linezolid of pneumococcal meningitis: a case series including penicillin-resistant strains. Clin Microbiol Infect. 2006;12:389–399
  40. Fiore AEM, Moroney JF, Farley MM, Harrison LH, Patterson JE, Jorgensen JH, et al. Clinical outcomes of meningitis caused by Streptococcus pneumoniae in the era of antibiotic resistance. Clin Infect Dis. 2000;30:71–77
  41. Fortnum H, Davis A. Hearing impairment in children after bacterial meningitis: incidence and resource implications. Bri J Audiol. 1993;27:43–52
  42. Grimwood K, Nolan TM, Bond L, Anderson VA, Catroppa C, Keir EH, et al. Risk factors for adverse outcomes of bacterial meningitis. J Paediatr Child Health. 1996;32:457–462
  43. Hanna JNW, Wild BE. Bacterial meningitis in children under five years of age in Western Australia. Med J Aust. 1991;155:160–164
  44. Hoogman M, van de Beek D, Weisfelt M, de Gans J, Schmand B. Cognitive outcome in adults after bacterial meningitis. J Neurol Neurosurg Psychiatr. 2007;78:1092–1096
  45. Husain E, Chawla R, Dobson S, Dele Davies H. Epidemiology and outcome of bacterial meningitis in Canadian children: 1998–1999. Clin Invest Med. 2006;29:131–135
  46. Kaaresen PIF, Flaegstad T. Prognostic factors in childhood bacterial meningitis. International Journal of Paediatrics Acta Paediatr. 1995;84:873–878
  47. Kallio MJT, Kilpi T, Anttila M, Peltola H. The effect of a recent previous visit to a physician on outcome after childhood bacterial meningitis. J Am Med Assoc. 1994;272:787–791
  48. Kastenbauer S, Pfister HW. Pneumococcal meningitis in adults: spectrum of complications and prognostic factors in a series of 87 cases. Brain. 2003;126:1015–1025[see comment]
  49. Kennedy WAH, Hoyt MJ, McCracken GH. The role of corticosteroid therapy in children with pneumococcal meningitis. Am J Dis Child. 1991;145:1374–1378
  50. King SML, Law B, Langley JM, Huerter H, Bremner D, Wang EE, et al. Dexamethasone therapy for bacterial meningitis: better never than late?. Can J Infect Dis. 1994;5:210–215
  51. King BA, Richmond P, King BA, Richmond P. Pneumococcal meningitis in Western Australian children: epidemiology, microbiology and outcome. J Paediatr Child Health. 2004;40:611–615
  52. Kirkpatrick B, Reeves DS, MacGowan AP. A review of the clinical presentation, laboratory features, antimicrobial therapy and outcome of 77 episodes of pneumococcal meningitis occurring in children and adults. J Infect. 1994;29:171–182
  53. Kornelisse RFW, Westerbeek CML, Spoor AB, van der Heijde B, Spanjaard L, Neijens HJ, et al. Pneumococcal meningitis in children: prognostic indicators and outcome. Clin Infect Dis. 1995;21:1390–1397
  54. Korshin A, Koster-Rasmussen R, Meyer CN, Danish Bacterial Meningitis Group . Adjunctive steroid treatment: local guidelines and patient outcome in adult bacterial meningitis. Scand J Infect Dis. 2007;39:963–968
  55. Kragsbjerg P, Kallman J, Olcen P. Pneumococcal meningitis in adults. Scand J Infect Dis. 1994;26:659–666
  56. Lazzarini L, Toti M, Fabris P, Conti E, Magni G, Mazzotta F, et al. Clinical features of bacterial meningitis in Italy: a multicenter prospective observational study. J Chemother. 2008;20:478–487
  57. Ma W, Shang-Feaster G, Okada PJ, Kernie SG. Elevated cerebrospinal fluid levels of glutamate in children with bacterial meningitis as a predictor of the development of seizures or other adverse outcomes. Pediatr Crit Care Med. 2003;4:170–175
  58. McCulloch R, Martin K, Robertson C. Bacterial meningitis: audiological follow-up - closing the audit cycle. Clin Governance. 2003;8:104–107
  59. McIntyre PB, Macintyre CR, Gilmour R, Wang H, McIntyre PB, Macintyre CR, et al. A population based study of the impact of corticosteroid therapy and delayed diagnosis on the outcome of childhood pneumococcal meningitis. Arch Dis Child. 2005;90:391–396
  60. Nathanson S, Deschenes G. Prognosis of Streptococcus pneumoniae-induced hemolytic uremic syndrome. Pediatr Nephrol. 2001;16:362–365
  61. Ohga S, Okada K, Ueda K, Takada H, Ohta M, Aoki T, et al. Cerebrospinal fluid cytokine levels and dexamethasone therapy in bacterial meningitis. J Infect. 1999;39:55–60
  62. Oostenbrink R, Maas M, Moons KGM, Moll HA. Sequelae after bacterial meningitis in childhood. Scand J Infect Dis. 2002;34:379–382
  63. Ostergaard C, Konradsen HB, Samuelsson S. Clinical presentation and prognostic factors of Streptococcus pneumoniae meningitis according to the focus of infection. BMC Infect Dis. 2005;5:93
  64. Ostergaard C, Hoiby N, Konradsen HB, Samuelsson S, Ostergaard C, Hoiby N, et al. Prehospital diagnostic and therapeutic management of otogenic Streptococcus pneumoniae meningitis. Scand J Infect Dis. 2006;38:172–180
  65. Pagliano P, Fusco U, Attanasio V, Rossi M, Pantosti A, Conte M, et al. Pneumococcal meningitis in childhood: a longitudinal prospective study. FEMS Immunol Med Microbiol. 2007;51:488–495
  66. Pfister HW, Feiden W, Einhaupl KM, Pfister HW, Feiden W, Einhaupl KM. Spectrum of complications during bacterial meningitis in adults. Results of a prospective clinical study. Arch Neurol. 1993;50:575–581
  67. Rajasingham CR, Bonsu BK, Chapman JI, Cohen DM, Barson WJ. Serious neurologic sequelae in cases of meningitis arising from infection by conjugate vaccine-related and nonvaccine-related serogroups of Streptococcus pneumoniae. Pediatr Infect Dis J. 2008;27:771–775
  68. Richardson MP, Reid A, Tarlow MJ, Rudd PT, Richardson MP, Reid A, et al. Hearing loss during bacterial meningitis. Arch Dis Child. 1997;76:134–138
  69. Schutze GEM, Mason EO, Barson WJ, Kim KS, Wald ER, Givner LB, et al. Invasive pneumococcal infections in children with asplenia. Pediatr Infect Dis J. 2002;21:278–282
  70. Shackley F, Knox K, Morris JB, Crook D, Griffiths D, Mayon-White R, et al. Outcome of invasive pneumococcal disease: a UK based study. Oxford Pneumococcal Surveillance Group. Arch Dis Child. 2000;83:231–233
  71. Syriopoulou V, Daikos GL, Soulis K, Michos A, Alexandrou H, Pavlopoulou I, et al. Epidemiology of invasive childhood pneumococcal infections in Greece. International Journal of Paediatrics Acta Paediatr Supplement. 2000;435:30–34
  72. Syrogiannopoulos GA, Lourida AN, Theodoridou MC, Pappas IG, Babilis GC, Economidis JJ, et al. Dexamethasone therapy for bacterial meningitis in children: 2- versus 4-day regimen. J Infect Dis. 1994;169:853–858
  73. Tan TQS. Antibiotic therapy and acute outcome of meningitis due to Streptococcus pneumoniae considered intermediately susceptible to broad-spectrum cephalosporins. Antimicrobial Agents Chemother. 1994;38:918–923
  74. Tucci M, Lebel MH, Gauthier M, Farrell CA, Lacroix J. Admission to a pediatric intensive care unit for bacterial meningitis: review of 168 cases. J Intensive Care Med. 1995;10:253–260
  75. Wald ER, Kaplan SL, Mason EO, Sabo D, Ross L, Arditi M, et al. Dexamethasone therapy for children with bacterial meningitis. Meningitis study group. Pediatrics. 1995;95:21–28
  76. Waters AMK, Kerecuk L, Luk D, Haq MR, Fitzpatrick MM, Gilbert RD, et al. Hemolytic uremic syndrome associated with invasive pneumococcal disease: the United Kingdom experience. J Pediatr. 2007;151:140–144
  77. Wellman MBS, Sommer DD, McKenna J. Sensorineural hearing loss in postmeningitic children. Otol Neurotol. 2003;24:907–912

PII: S0163-4453(10)00128-3

doi: 10.1016/j.jinf.2010.04.008

Journal of Infection
Volume 61, Issue 2 , Pages 114-124 , August 2010

Article Tools

* Image Usage & Resolution